Bausch + Lomb (BLCO) Q3 Results Sharpen Profit Recovery As Valuation Lags

Bausch + Lomb stock went nowhere in regular trading, holding flat at US$20.40, even as Q3 2026 results landed with a cleaner earnings story than the price action suggests. The eye care group swung back to profit with basic earnings per share of US$0.09 and produced US$1.375b in revenue, while adjusted EBITDA reached US$325m on a 23.6% margin. In the short term the quote looks sleepy. The larger tension is that these improving profits and cash generation sit against a multi year record of losses and a valuation that still prices the company below many medical equipment peers.

Like the earnings rebuild at Bausch + Lomb but uneasy about that long history of losses and a still-muted valuation? Take a look at our 30 high quality undervalued stocks if you want a list of companies that pair stronger profitability with balance sheets already aligned with their income statements.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$1.375b vs. US$1.281b (up about 7%)
• Net Income (Q3 2026 vs. Q3 2025): profit of US$32m vs. loss of US$28m (swing back to profitability)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.09 per share vs. loss of US$0.08 per share (clear move into positive earnings)
• Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025): 23.6%, compared with the prior year level implied by 34% year-on-year EBITDA growth (stronger profitability on each dollar of revenue)

Guidance and margins are rising faster than revenue at Bausch + Lomb. Ask Charlie what makes Bausch + Lomb’s margin gains look durable.

Bausch + Lomb’s Bull Story Meets Hard Numbers

Bulls argue that Bausch + Lomb can convert pipeline depth and mix upgrades into a meaningfully more profitable eye care platform.

"Bullish analysts expect Bausch + Lomb to build on its growing dry eye, surgical and consumer eye care franchises and turn the broad late stage pipeline into a larger, more profitable eye health business."

Q3 results hit several of those milestones. Dry eye therapies such as Miebo and Xiidra contributed to 11% constant currency pharmaceutical growth. Premium IOLs in Surgical rose sharply while equipment sales were managed to seed more consumables. Adjusted EBITDA margin reached 23.6% and free cash flow was US$178m, with net leverage reduced to 4.1x, aligning with a thesis built on mix, efficiency and cash conversion.

One Narrative disagrees with today's price. → See where this Narrative says Bausch + Lomb should trade.

Bausch + Lomb Bears Focus On Returns Risk

Bears question whether Bausch + Lomb is just recycling capital into long dated eye projects instead of lifting returns. The sharpest concern centers on pipeline spend that may not translate into durable earnings.

"Previously, dry eye projects were framed as broad pipeline support for long term growth. Now, discontinued BL1107 and the longer dated implant for geographic atrophy are seen as potential sinks of R&D capital that may not lift revenue or earnings meaningfully."

Q3 points the other way on near term payback. Pharmaceuticals revenue rose, dry eye drugs grew strongly and adjusted EBITDA margin reached 23.6%. R&D stayed near 8% of sales while free cash flow hit US$178m and net leverage moved to 4.1x. The feared cash drain is not visible yet.

Hunt Quiet Disconnects In Plain Sight

Bausch + Lomb just showed how a cleaner profit story can leave its share price unchanged. The real opportunity is finding stocks that could be undervalued before the market responds to them.

• Company 1 - 20% below our estimate - grows a teahouse network where rising overseas GMV and membership scale reshape franchise economics.
• Company 2 - 31% below our estimate - turns long duration optical and solar supply agreements into production runs tied to digital and energy infrastructure projects.
• Company 3 - 26% below our estimate - adds customers to a low cost digital bank as rising revenue per active user reshapes mass market lending unit economics.

Those are three of them. See all 30 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com